Phenotypic analysis of human CYP2C9 polymorphisms using fluorine-substituted tolbutamide

Area of Science:

• Pharmacology
• Enzymology
• Medicinal Chemistry

Background:

• Cytochrome P450 2C9 (CYP2C9) is a key enzyme in drug metabolism.
• Polymorphisms in CYP2C9 affect drug efficacy and safety.
• Understanding substrate interactions with CYP2C9 variants is crucial for personalized medicine.

Purpose of the Study:

• To investigate the impact of fluorine substitution on tolbutamide (TB) hydroxylation by different CYP2C9 isoforms.
• To evaluate the potential of fluorinated analogs as tools for CYP2C9 phenotyping.

Main Methods:

• Recombinant human CYP2C9*1, CYP2C9*2, and CYP2C9*3 were used.
• Hydroxylation of tolbutamide (TB) and 3'-fluoro-tolbutamide (3'-F-TB) was analyzed.
• Kinetic parameters (Km) and metabolite ratios were determined.

Main Results:

• Fluorine substitution generally reduced the Km for TB hydroxylation across CYP2C9 isoforms.
• The greatest reduction in Km was observed with CYP2C9*3.
• The hydroxylated metabolite ratio of 3'-F-TB was significantly higher with CYP2C9*3 compared to CYP2C9*1 and CYP2C9*2.

Conclusions:

• Fluorine substitution alters the metabolic profile of tolbutamide by CYP2C9.
• Fluorine-substituted analogs show potential as tools for phenotyping polymorphic CYP isoforms.
• Metabolite profiling of fluorinated analogs may offer a novel approach for drug metabolism studies.